DE602004016729D1 - 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES - Google Patents

1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES

Info

Publication number
DE602004016729D1
DE602004016729D1 DE602004016729T DE602004016729T DE602004016729D1 DE 602004016729 D1 DE602004016729 D1 DE 602004016729D1 DE 602004016729 T DE602004016729 T DE 602004016729T DE 602004016729 T DE602004016729 T DE 602004016729T DE 602004016729 D1 DE602004016729 D1 DE 602004016729D1
Authority
DE
Germany
Prior art keywords
treatment
acid derivatives
phenylalkancarbonic
diseases
neurodeegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004016729T
Other languages
German (de)
Inventor
Luca Raveglia
Ilaria Peretto
Stefano Radaelli
Bruno Pietro Imbimbo
Andrea Rizzi
Gino Villetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20030311 external-priority patent/ITMI20030311A1/en
Priority claimed from ITMI20032068 external-priority patent/ITMI20032068A1/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of DE602004016729D1 publication Critical patent/DE602004016729D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C07C15/14—Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.
DE602004016729T 2003-02-21 2004-02-19 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES Expired - Lifetime DE602004016729D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20030311 ITMI20030311A1 (en) 2003-02-21 2003-02-21 2-FENYL-2-DIALKYL-ACETIC ACIDS FOR THE TREATMENT OF ALZHEIMER DISEASE.
ITMI20032068 ITMI20032068A1 (en) 2003-10-23 2003-10-23 DERIVATIVES OF 1-PHENYLCYCLOALCANCARBOSSYIC ACID FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
PCT/EP2004/001596 WO2004074232A1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DE602004016729D1 true DE602004016729D1 (en) 2008-11-06

Family

ID=32910543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016729T Expired - Lifetime DE602004016729D1 (en) 2003-02-21 2004-02-19 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES

Country Status (17)

Country Link
US (3) US7662995B2 (en)
EP (1) EP1594833B1 (en)
JP (1) JP4472691B2 (en)
KR (2) KR101088272B1 (en)
AT (1) ATE409176T1 (en)
AU (1) AU2004213145B2 (en)
BR (1) BRPI0407662B8 (en)
CA (1) CA2514384C (en)
CY (1) CY1108514T1 (en)
DE (1) DE602004016729D1 (en)
DK (1) DK1594833T3 (en)
ES (1) ES2312964T3 (en)
HK (1) HK1087398A1 (en)
NO (1) NO333118B1 (en)
PT (1) PT1594833E (en)
SI (1) SI1594833T1 (en)
WO (1) WO2004074232A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR101088272B1 (en) * 2003-02-21 2011-11-30 키에시 파르마슈티시 엣스. 피. 에이. 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2007528857A (en) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド Pharmaceutical methods, dosing regimens and dosage forms for the treatment of Alzheimer's disease
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (en) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Veneers for walls, retaining walls and the like.
WO2006016219A2 (en) 2004-08-03 2006-02-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
KR20080039876A (en) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. High drug load formulations and dosage forms
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
JO3598B1 (en) 2006-10-10 2020-07-05 Infinity Discovery Inc Boronic acids and esters as inhibitors of fatty acid amide hydrolase
JP2011507909A (en) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド Tetrasubstituted benzene
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
PT2462098E (en) * 2009-08-04 2013-12-04 Chiesi Farma Spa Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
CN102834401B (en) 2010-02-03 2016-08-24 无限药品股份有限公司 Inhibitors of fatty acid amide hydrolase
CN106431900A (en) 2010-04-01 2017-02-22 奇斯药制品公司 Novel polymorphs and salts
ES2526522T3 (en) 2010-04-21 2015-01-13 Chiesi Farmaceutici S.P.A. 1- (2-Fluorobiphenyl-4-yl) alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
CA2801449A1 (en) * 2010-06-04 2011-12-08 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
CA2869418A1 (en) 2012-04-04 2013-10-10 Chiesi Farmaceutici S.P.A. Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (en) 2013-03-15 2017-01-18 ファイザー・インク Indazole compounds that activate AMPK
EP2818460A1 (en) 2013-06-24 2014-12-31 ZaCh System S.p.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
RU2015153818A (en) 2013-06-24 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. IMPROVED METHOD FOR PRODUCING 1- (2-fluoro [1, 1-biphenyl] -4-yl) -cyclopropanecarboxylic acid derivatives
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
US20150335596A1 (en) 2014-05-26 2015-11-26 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
AU2022338032A1 (en) 2021-08-31 2024-03-07 Cerespir Incorporated Co-crystals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE735385A (en) * 1968-07-04 1969-12-01
JPS4994680A (en) 1973-01-22 1974-09-09
JPS5046669A (en) 1973-03-28 1975-04-25
JPS58177977A (en) 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd 4-phenylpyrazole
AU2936295A (en) * 1994-07-13 1996-02-16 Taisho Pharmaceutical Co., Ltd. Thiopheneacetic acid derivative
JPH0994680A (en) * 1995-07-24 1997-04-08 Toyota Motor Corp Friction welding equipment
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP2006517925A (en) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Geminal disubstituted NSAID derivatives as Aβ42 lowering agents
KR101088272B1 (en) * 2003-02-21 2011-11-30 키에시 파르마슈티시 엣스. 피. 에이. 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006016219A2 (en) * 2004-08-03 2006-02-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Also Published As

Publication number Publication date
DK1594833T3 (en) 2008-12-15
US8314268B2 (en) 2012-11-20
JP4472691B2 (en) 2010-06-02
CY1108514T1 (en) 2014-04-09
WO2004074232A8 (en) 2005-09-09
ATE409176T1 (en) 2008-10-15
NO20053855L (en) 2005-11-21
EP1594833B1 (en) 2008-09-24
US20070060752A1 (en) 2007-03-15
US20100099768A1 (en) 2010-04-22
SI1594833T1 (en) 2008-12-31
KR101152448B1 (en) 2012-07-02
US7662995B2 (en) 2010-02-16
AU2004213145A1 (en) 2004-09-02
KR20110057227A (en) 2011-05-31
CA2514384C (en) 2012-04-10
BRPI0407662B1 (en) 2019-11-12
US8022250B2 (en) 2011-09-20
ES2312964T3 (en) 2009-03-01
WO2004074232A1 (en) 2004-09-02
KR101088272B1 (en) 2011-11-30
NO20053855D0 (en) 2005-08-18
HK1087398A1 (en) 2006-10-13
NO333118B1 (en) 2013-03-04
BRPI0407662A (en) 2006-03-01
EP1594833A1 (en) 2005-11-16
AU2004213145B2 (en) 2010-05-13
BRPI0407662B8 (en) 2021-05-25
PT1594833E (en) 2008-12-03
JP2006518351A (en) 2006-08-10
CA2514384A1 (en) 2004-09-02
US20110288175A1 (en) 2011-11-24
KR20050104369A (en) 2005-11-02

Similar Documents

Publication Publication Date Title
ATE409176T1 (en) 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
DE602004020072D1 (en) 1,2,3,4-TETRASUBSTITUTED INDOL FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
DE60320007D1 (en) PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
ATE396973T1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer&#39;s disease
ATE383853T1 (en) ARYLESTIC ACIDS AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
UY27993A1 (en) DERIVATIVES OF 4-PIRROLIDINO-FENIL-BENCIL ETER
DE60312736D1 (en) 1,2,4-TRIAMINOBENZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
DE60204466D1 (en) INTEGRINMA TREATMENT FOR THE TREATMENT OF EYE DISEASES
ATE399758T1 (en) DERIVATIVES OF 1-PHENYLALKANECARBONIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
ATE437855T1 (en) (4,5,6,7-TETRAHYDRO-1H-INDOL-7-YL)ACETIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
DE60326069D1 (en) 4- (HETEROCYCLYL) -BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
NO20076405L (en) Use of 24-nor-UDCA
DE60016047D1 (en) DIHYDROBENZOPYRANE, DIHYDROBENZOTHIOPYRANE AND TETRAHYDROCHINOLINE FOR THE TREATMENT OF COX-2-DEPENDENT DISEASES
ATE464048T1 (en) TREATMENT OF ALZHEIMER&#39;S DISEASE AND RELATED CONDITIONS
DE60124093D1 (en) S-methyl-dihydro-ziprasidone for the treatment of eye diseases.
WO2007048034A3 (en) Use of androgens for the treatment of parkinson&#39; s disease
DE602004024992D1 (en) USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITES
DE60234031D1 (en) MEDICINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES
DE60308862D1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DISEASES RELATED TO DIABETES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition